OMISIRGE Sales Forecast

Key Factors Driving OMISIRGE Growth

First FDA-Approved Expanded Cord-Blood Cell Therapy

A major growth catalyst is regulatory approval and first-in-class positioning.

• The US Food and Drug Administration approved Omisirge in April 2023 for adults and pediatric patients (≥12 years) with hematologic malignancies undergoing umbilical cord blood transplantation after myeloablative conditioning.
• The therapy received Breakthrough Therapy designation, Priority Review, and Orphan Drug designation, highlighting the unmet medical need in stem-cell transplant settings.

Demonstrated Clinical Benefits in Stem Cell Transplantation

Clinical efficacy data from the pivotal randomized Phase III trial strongly support the therapy’s value.

Key results include:

• Median neutrophil recovery time: 12 days with Omisirge vs 22 days with standard cord blood transplantation.
• Infection rates within 100 days: 39% with Omisirge vs 60% with standard cord blood.

Faster neutrophil recovery significantly reduces infection risk and hospital complications after transplantation, which is a critical outcome for patients with blood cancers such as leukemia or lymphoma. These clinical advantages drive physician adoption and hospital demand.

Expanding Access to Stem Cell Transplantation

Another key growth driver is Omisirge’s ability to expand access to transplantation for patients lacking matched donors.

Many patients with hematologic malignancies do not have a fully matched stem-cell donor, particularly those from minority ethnic backgrounds. Cord blood transplantation can be used in these cases, but traditional cord blood transplants have slower immune recovery.

Omisirge’s cell expansion technology enhances cord-blood stem cells, enabling:

• Higher stem-cell doses
• Faster engraftment
• Improved transplant outcomes

Potential Expansion Into Additional Indications

Label expansion into other hematologic diseases could significantly increase the therapy’s addressable market.

Ongoing development includes:

• Severe Aplastic Anemia (SAA): the company submitted a supplemental Biologics License Application, which received FDA Priority Review.

Severe aplastic anemia is a rare but life-threatening bone-marrow failure disorder often treated with stem-cell transplantation. Approval in this indication could expand Omisirge’s patient population and increase revenue potential.

Manufacturing Expansion and Strategic Partnerships

Scaling manufacturing capacity is another important growth factor for cell-based therapies.

To support commercial demand, Ayrmid/Gamida Cell has partnered with RoslinCT to manufacture Omisirge in the United States through technology transfer to a dedicated CGMP facility.

Benefits of this strategy include:

• Increased production capacity
• Reduced supply chain risks
• Ability to support higher patient demand across transplant centers

Manufacturing scalability is critical for commercializing advanced cell therapies.

Growing Market for Hematopoietic Stem Cell Transplantation

The global hematopoietic stem cell transplantation (HSCT) market continues to grow due to rising incidence of hematologic cancers such as leukemia, lymphoma, and myelodysplastic syndromes.

OMISIRGE Recent Developments

• In December 2025, Ayrmid announced that it has received US Food and Drug Administration (“FDA”) approval for Omisirge (Omidubicel) for the treatment of Severe Aplastic Anemia (SAA).

“OMISIRGE Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of OMISIRGE for approved indication like Aplastic anaemia and Haematological malignancies; as well as potential indication like Haemoglobinopathies, Myelodysplastic syndromes, Sickle cell anaemia, and Thalassaemia in the 7MM. A detailed picture of OMISIRGE’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the OMISIRGE for approved and potential indications. The OMISIRGE market report provides insights about OMISIRGE’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OMISIRGE performance, future market assessments inclusive of the OMISIRGE market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OMISIRGE sales forecasts, along with factors driving its market.

OMISIRGE Drug Summary

OMISIRGE (omidubicel) is an FDA-approved cryopreserved allogeneic hematopoietic progenitor cell therapy derived from umbilical cord blood, manufactured by Gamida Cell using proprietary nicotinamide (NAM) modification technology to enrich CD34+ hematopoietic progenitor cells (HPCs) while including supportive cell populations like myelomonocytic cells, dendritic cells, and granulocytes in its cultured fraction (CF) and non-cultured fraction (NF), both from the same patient-specific cord blood unit. Indicated for adults and pediatric patients 12 years and older with hematologic malignancies undergoing umbilical cord blood transplantation (CBT) after myeloablative conditioning to accelerate neutrophil recovery and decrease infection risk, as well as for those 6 years and older with severe aplastic anemia (SAA) post-reduced intensity conditioning, it leverages NAM to mitigate ex vivo stress-induced differentiation and apoptosis, enabling faster engraftment (median 12 days to neutrophils vs. 21 days for standard CBT in Phase III trials). Administered intravenously as a thawed suspension post-thaw dilution, it offers a shorter time to platelet recovery and reduced early graft failure, though monitoring for graft-versus-host disease, infections, and infusion reactions remains essential. The report provides OMISIRGE’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the OMISIRGE Market Report

The report provides insights into:

• A comprehensive product overview including the OMISIRGE MoA, description, dosage and administration, research and development activities in approved indications like Aplastic anaemia and Haematological malignancies; as well as potential indication like Haemoglobinopathies, Myelodysplastic syndromes, Sickle cell anaemia, and Thalassaemia.
• Elaborated details on OMISIRGE regulatory milestones and other development activities have been provided in OMISIRGE market report.
• The report also highlights OMISIRGE‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The OMISIRGE market report also covers the patents information, generic entry and impact on cost cut.
• The OMISIRGE market report contains current and forecasted OMISIRGE sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The OMISIRGE market report also features the SWOT analysis with analyst views for OMISIRGE in approved and potential indications.

Methodology

The OMISIRGE market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OMISIRGE Analytical Perspective by DelveInsight

In-depth OMISIRGE Market Assessment

This OMISIRGE sales market forecast report provides a detailed market assessment of OMISIRGE for approved indication like Aplastic anaemia and Haematological malignancies; as well as potential indication like Haemoglobinopathies, Myelodysplastic syndromes, Sickle cell anaemia, and Thalassaemia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OMISIRGE sales data uptil 2034.

OMISIRGE Clinical Assessment

The OMISIRGE market report provides the clinical trials information of OMISIRGE for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

OMISIRGE Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

OMISIRGE Market Potential & Revenue Forecast

• Projected market size for the OMISIRGE and its key indications
• Estimated OMISIRGE sales potential (OMISIRGE peak sales forecasts)
• OMISIRGE Pricing strategies and reimbursement landscape

OMISIRGE Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• OMISIRGE Market positioning compared to existing treatments
• OMISIRGE Strengths & weaknesses relative to competitors

OMISIRGE Regulatory & Commercial Milestones

• OMISIRGE Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

OMISIRGE Clinical Differentiation

• OMISIRGE Efficacy & safety advantages over existing drugs
• OMISIRGE Unique selling points

OMISIRGE Market Report Highlights

• In the coming years, the OMISIRGE market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The OMISIRGE companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OMISIRGE’s dominance.
• Other emerging products for Aplastic anaemia and Haematological malignancies; as well as potential indication like Haemoglobinopathies, Myelodysplastic syndromes, Sickle cell anaemia, and Thalassaemia are expected to give tough market competition to OMISIRGE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OMISIRGE in approved and potential indications.
• Analyse OMISIRGE cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted OMISIRGE sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OMISIRGE in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of OMISIRGE? How strong is OMISIRGE’s clinical and commercial performance?
• What is OMISIRGE’s clinical trial status in each individual indications such as Aplastic anaemia and Haematological malignancies; as well as potential indication like Haemoglobinopathies, Myelodysplastic syndromes, Sickle cell anaemia, and Thalassaemia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OMISIRGE Manufacturers?
• What are the key designations that have been granted to OMISIRGE for approved and potential indications? How are they going to impact OMISIRGE’s penetration in various geographies?
• What is the current and forecasted OMISIRGE market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of OMISIRGE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to OMISIRGE for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is OMISIRGE? What is the duration of therapy and what are the geographical variations in cost per patient?